Stephen Vincent, MD
Neurology · Idaho Falls, IDNPI 1932221306
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $112,161 of the $155,508 with a category attached, or 72.1%. 38 manufacturers reported payments, led by Genentech USA, Inc. at 34.7% of the total. Reporting peaked in 2019 at $69,575 and has fallen 99.3% since, to $457 in 2025. Among neurology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 594 payments — averaging $261.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$54K
- E.r. Squibb & Sons, L.L.C.$37K
- Sanofi$35K
- Bristol Myers Squibb$15K
- EMD Serono, Inc.$9K
- AbbVie$2K
- plus $4K from 32 others
Across 8 payments — averaging $263.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$2K
What the payments were for
- Consulting fees$19,36212%
- Speaking & faculty fees$112,16172%
- Travel & lodging$13,2609%
- Food & beverage$10,4257%
- Education$3000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 69 | $54,023 |
| E.r. Squibb & Sons, L.L.C. | 42 | $37,079 |
| Sanofi | 73 | $34,591 |
| Bristol Myers Squibb | 104 | $15,203 |
| EMD Serono, Inc. | 51 | $8,862 |
| AbbVie(2 entities) | 107 | $1,886 |
| Biogen | 46 | $1,072 |
| Boston Scientific | 13 | $1,048 |
| Teva Pharmaceuticals USA, Inc. | 10 | $330 |
| Novartis | 25 | $298 |
| TG Therapeutics, Inc. | 5 | $118 |
| Acadia Pharmaceuticals Inc | 4 | $82 |
| Lilly USA, LLC | 3 | $62 |
| Acorda Therapeutics, Inc | 3 | $59 |
| Livanova USA, Inc. | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 3 | $58 |
| Neurocrine Biosciences, Inc. | 3 | $57 |
| Merz Pharmaceuticals, LLC | 2 | $56 |
| Neurelis, Inc. | 3 | $55 |
| Argenx US, Inc. | 3 | $54 |
| Lundbeck LLC | 2 | $53 |
| AstraZeneca | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $39 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Harmony Biosciences LLC | 1 | $28 |
| SK Life Science, Inc. | 1 | $26 |
| Abbott | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Cala Health, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 2 | $21 |
| Medtronic | 1 | $19 |
| CSL Behring | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,508 in reported general payments places this provider in the 95th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 13 | $34,126 |
| Aimovig AutoinjectorErenumab-Aooe | 32 | $30,565 |
| Levetiracetam | 281 | $12,271 |
| QuliptaAtogepant | 11 | $12,260 |
| Modafinil | 57 | $11,256 |
| Emgality PenGalcanezumab-Gnlm | 15 | $10,862 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 487 | $10,827 |
| Mycophenolate Mofetil | 36 | $8,577 |
| Zonisamide | 91 | $8,135 |
| Pyridostigmine Bromide | 39 | $6,197 |
| Dalfampridine ErDalfampridine | 14 | $5,961 |
| FingolimodFingolimod Hcl | 25 | $5,358 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 44 | $3,647 |
| Gabapentin | 185 | $2,949 |
| Carbidopa | 11 | $2,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Aptiom | $58 | $34,12613 claims |
| AbbVieQulipta | $1,886 | $12,26011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 59 neurology providers in Idaho.
Other neurology in Idaho Falls
- Bradford TalcottIdaho Falls$252K
- Erich GarlandIdaho Falls$33K
- Shahzaib TariqIdaho Falls$647
- Lawrence GreenNampa$193K
- Nina BozinovCoeur D Alene$76K
- Angela PanaCoeur D Alene$37K
- Sergei KashirnyBoise$20K
- Richard HammondTwin Falls$16K
- Kylie AbeMeridian$16K
- John SteffensTwin Falls$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.